Orphan drugs offer critical treatment options for rare diseases, improving quality of life for underserved patients and ...

NDAQ:ZLAB) Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell ...

Zydus Lifesciences announced that Usnoflast, a treatment for amyotrophic lateral sclerosis (ALS), has received Orphan Drug Designation from the US FDA. This designation supports the development of ...

Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases and areas of unmet medical need, has a portfolio of products aimed at ...

GRAFAPEX™ (treosulfan) for injection is approved by the FDA for sale and use in the United States only and is not intended for export outside the United States. Medexus makes no representation that ...

Virginia’s proposed prescription drug affordability board would positioning the government as an arbiter of medical value and access, the Rare Access Action Project’s Michael Eging ...

Nuvalent, Inc. shares have fallen approximately 30% after promising updates on its two lead NSCLC candidates rallied the stock to all-time highs. Read the full report on the stock here.

Dr. Imbert brings 25 years of strategic clinical to commercial-stage manufacturing and drug development experience SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, ...

House Study Bill 15 criminalizes the act of smuggling noncitizens for pay or other benefits. Smuggling actions would include ...

Based on recent policy signals and statements from incoming administration officials, a picture of potential regulatory and policy changes that ...

SOUTH SAN FRANCISCO - Pliant Therapeutics, Inc. (NASDAQ: PLRX), a biotechnology company focused on fibrotic diseases with a market capitalization of $674 million, has named Delphine Imbert, Ph.D., as ...